- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 25.11. | Calling all rising stars in pharma marketing: Nominations open for Fierce feature series | ||
| 25.11. | Sarepta gets FDA's go-ahead to study immunosuppressive Elevidys regimen in bid to reverse label restriction | ||
| 25.11. | AbbVie short film showcases 'Second Winds' of life after CLL diagnosis | ||
| 25.11. | Pharma pros skeptical of letting AI loose on regulatory compliance submissions: survey | ||
| 25.11. | Lawmakers probe FDA's new priority voucher program, cite corruption and rushed review concerns | ||
| 25.11. | Novartis to cut 550 jobs at plant in Switzerland by end of 2027 | ||
| 25.11. | Novartis scores FDA approval for new version of SMA gene therapy, prices at $2.59M | ||
| 25.11. | Angelini faces UK marketing watchdog's wrath after speaker blasts 'stupid' EMA | ||
| 24.11. | SK Life Science Xcopri ad meets a roadblock with FDA untitled letter | ||
| 24.11. | Novo shares tumble after 2 trial misses for semaglutide in Alzheimer's disease | ||
| 24.11. | Merck's partner Kelun touts phase 3 win for ADC-Keytruda combo in first-line lung cancer | ||
| 21.11. | AstraZeneca boosts its presence in Maryland with $2B manufacturing investment | ||
| 21.11. | FDA grants game-changing perioperative approval to Padcev, Keytruda combo in bladder cancer | ||
| 21.11. | FDA launches investigation into Takeda's Adzynma following reported pediatric death | ||
| 21.11. | Australian government rejects Cosette's proposed Mayne Pharma buyout, citing 'national interest' | ||
| 21.11. | Texas files suit against Sanofi, BMS over 'deceptive' Plavix marketing | ||
| 21.11. | GSK's Tesaro, AnaptysBio lock horns in court over Jemperli agreement | ||
| 21.11. | Semaglutide compounder drops claims after Novo Nordisk challenge | ||
| 20.11. | Moderna takes out $1.5B loan, outlines commercial and R&D strategy in bid to break even by 2028 | ||
| 20.11. | Sun Pharma shines a light on diabetic retinopathy in SeeBeyondSugar campaign | ||
| 20.11. | With 2 FDA nods for Eylea HD, Regeneron is 'no longer fighting Vabysmo with both hands tied behind its back,' analyst says | ||
| 20.11. | Pfizer, Tris Pharma ink $41.5M deal to settle ADHD drug fraud allegations in Texas | ||
| 20.11. | Indian API maker Cdymax hit with FDA warning letter tied to drug ingredients testing | ||
| 19.11. | Bayer edges onto Boehringer's turf with FDA nod for HER2-mutated lung cancer med Hyrnuo | ||
| 19.11. | Moderna blueprints $140M plant in bid to bring end-to-end mRNA production to US |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .